Simon Beyaert
Overview
Explore the profile of Simon Beyaert including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
24
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Beyaert S, Loriot A, Machiels J, Schmitz S
Int J Mol Sci
. 2025 Mar;
26(5).
PMID: 40076457
Afatinib-induced tumor and microenvironment modifications in head and neck squamous cell carcinoma were evaluated by spatial transcriptomics in surgical specimens and RNA-sequencing in tumor biopsies of patients included in the...
2.
Van den Bossche V, Vignau J, Vigneron E, Rizzi I, Zaryouh H, Wouters A, et al.
Nat Commun
. 2025 Jan;
16(1):1237.
PMID: 39890801
Anti-epidermal growth factor receptor (EGFR) therapy (cetuximab) shows a limited clinical benefit for patients with locally advanced or recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), due to the frequent...
3.
Beyaert S, Borys A, Baldin P, Dahou H, Magremanne M, Mahy P, et al.
Oral Oncol
. 2024 May;
154:106869.
PMID: 38820890
Objectives: Primary objective was to evaluate the correlation between immune marker expression in baseline tumor biopsies and their respective surgical specimens in squamous cell carcinoma of the oral cavity (OCSCC)....
4.
Huyghe N, Benidovskaya E, Beyaert S, Daumerie A, Maestre Osorio F, Aboubakar Nana F, et al.
J Vis Exp
. 2023 Jun;
(196).
PMID: 37335095
The tumor microenvironment (TME) is composed of a plethora of different cell types, such as cytotoxic immune cells and immunomodulatory cells. Depending on its composition and the interactions between cancer...
5.
Beyaert S, Machiels J, Schmitz S
Cancers (Basel)
. 2021 Dec;
13(23).
PMID: 34885150
In 2019, the FDA approved pembrolizumab, a monoclonal antibody targeting PD-1, for the first-line treatment of recurrent or metastatic head and neck cancers, despite only a limited number of patients...
6.
Hox V, Beyaert S, Bullens D, Couto M, Langer D, Hellings P, et al.
Allergy
. 2021 Feb;
76(9):2716-2729.
PMID: 33605430
Adequate nasal breathing is indispensable for athletes, and nasal symptoms have been shown to interfere with their subjective feeling of comfortable breathing and quality of life. Nasal symptoms are caused...
7.
Beyaert S, Hamoir M, van Maanen A, Gregoire V, Schmitz S
Eur J Surg Oncol
. 2019 Apr;
45(7):1188-1195.
PMID: 30940421
Introduction: The aim of this study was to assess the validity of a treatment strategy for T1N0 glottic squamous cell carcinoma. Methods: One hundred and seventeen patients were prospectively treated...
8.
Beyaert S, Pruijm M, Dine Qanadli S, Vollenweider P, Halfon M
Clin Nephrol
. 2017 Feb;
87 (2017)(5):255-260.
PMID: 28177278
Background: Polyarteritis nodosa (PAN) is a systemic vasculitis involving mainly medium-sized arteries and, rarely, small-sized arteries. The diagnosis is principally based on clinical exams, biopsy of an affected organ, and/or...